Nano-paclitaxel
The unique nanoparticulate formulation of the most widely used anticancer drug paclitaxel has been under development. Nanopaclitaxel was formulated to eliminate the safety issues associated with other approved paclitaxel preparations, such as Taxol , that use various detergents to help the paclitaxel molecule dissolve in water. Solubility in water is essential for administering drugs into the bloodstream. Unfortunately, the detergents used in other paclitaxel formulations can be toxic, requiring that patients receive additional medications to counteract those toxicities. Nanopaclitaxel overcome this solubility issue with unique nanoparticulate drug releasing and delivery system. Nanopaclitaxel is safer than Taxol , as well as more effective, in treating oncology patients because of the fact that patients could take larger doses of paclitaxel, thanks to the lack of detergents in the nanoparticulate formulation.

ALL-3
Numerous researches discovered that epithelial growth factor receptor Her-2 gene (EGFR Her-2) is not only a growth factor receptor, but also a networking receptor. It is the key role in fairly malignant tumor cell transformation. ALL-3 is a new chemical entity of EGFR Her-2 inhibitor, selectively inhibiting Her-2 receptor for the treatment oncology patients. Patent protection has been filed.